Quanterix to make $75M public offering

By LabPulse.com staff writers

August 8, 2019 -- Biomarker analysis firm Quanterix said it plans to make a public offering of $75 million shares of its common stock.

The company will grant underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock at the public offering price, it said; all shares will be sold by Quanterix.

J.P. Morgan Securities and SVB Leerink are joint book-running managers for the offering, and Canaccord Genuity is co-manager, according to the firm.

Quanterix boosts NfL assays with UmanDiagnostics acquisition
Quanterix is building its testing offerings for neurofilament light (NfL) -- an increasingly important biomarker in Alzheimer's disease and other neurological...
Cerebrospinal fluid test helps pinpoint dementia disorders
Testing for neurofilament light protein in cerebrospinal fluid appears to be helpful for differentiating some neurological conditions, such as frontotemporal...

Copyright © 2019 LabPulse.com

Last Updated np 8/8/2019 1:51:13 PM